扶正健脾消癌方联合mFOLFOX6方案治疗晚期大肠癌的临床研究

发布时间：2018-11-15 16:48

【摘要】：目的:观察扶正健脾消癌方联合mFOLFOX6方案治疗晚期大肠癌患者的中医症状积分、生活质量、体力状况、肿瘤标志物CEA和CA19-9值、免疫功能和毒副作用的变化,客观评价该治疗方案的临床疗效和安全性,为晚期大肠癌患者的综合治疗提供临床用药参考。方法:将60例晚期大肠癌患者随机分成两组,其中观察组29例(其中1例因转外院治疗脱落),对照组29例(其中1例因未按规定完成治疗剔除)。观察组治疗用药为中药扶正健脾消癌方联合mFOLFOX6方案化疗,对照组治疗用药为单纯化疗,14天为一周期,连续治疗2个周期。记录两组患者治疗前后的中医症候积分、体力状况、生活质量评分、肿瘤标志物水平及淋巴细胞亚群分型水平变化,记录治疗过程中的安全性评价指标,对记录的资料进行统计分析。结果:在中医症候积分改善方面,观察组总有效率89.66%,对照组总有效率31.03%,差异明显(P＜0.01);两组患者治疗后体力状况、生活质量较治疗前均得到改善,且治疗后观察组较对照组有明显优势(P＜0.05);两组患者治疗后血清CEA、CA19-9值较治疗前均下降,差异明显(P0.01),观察组治疗后血清CEA、CA19-9值下降水平较对照组差异明显(P＜0.05);观察组治疗后CD3+、CD4+及CD8+水平改变情况较对照组治疗后存在明显差异(P0.05);两组患者治疗中出现中性粒细胞减少、恶心呕吐、腹泻和周围神经毒性这四项不良反应具有统计学差异(P0.05)。结论:扶正健脾消癌方联合mFOLFOX6方案治疗晚期大肠癌患者时,在改善患者中医症候、提高体力状况和生活质量、增强免疫功能方面有显著疗效,可降低患者肿瘤标志物水平,同时也可减轻化疗过程中发生的一部分毒副反应。中医药联合化疗治疗晚期大肠癌较单纯化疗优势显著,为治疗晚期大肠癌提供了一种有效的综合治疗手段。
[Abstract]:Objective: to observe the changes of TCM symptom score, quality of life, physical condition, tumor markers CEA and CA19-9, immune function and toxic side effects in patients with advanced colorectal cancer treated with Fuzheng Jianpixiao recipe and mFOLFOX6 regimen. Objective to evaluate the clinical efficacy and safety of the treatment regimen, and to provide a clinical reference for the comprehensive treatment of advanced colorectal cancer patients. Methods: sixty patients with advanced colorectal cancer were randomly divided into two groups: the observation group (29 cases) and the control group (29 cases). The observation group was treated with Fuzheng Jianpi Xiao cancer prescription combined with mFOLFOX6 regimen, while the control group was treated with chemotherapy alone, 14 days as one cycle, 2 consecutive cycles. The scores of TCM symptoms, physical strength, quality of life, tumor markers and lymphocyte subsets were recorded before and after treatment in both groups, and the safety evaluation indexes were recorded. Statistical analysis of recorded data. Results: the total effective rate of observation group was 89.666.The total effective rate of control group was 31.03.The difference was significant (P < 0.01). After treatment, the physical condition and quality of life of the two groups were improved, and the observation group had obvious advantages compared with the control group (P < 0.05). After treatment, the serum CEA,CA19-9 level in the two groups was significantly lower than that before treatment (P0.01), and the level of serum CEA,CA19-9 in the observation group was significantly lower than that in the control group (P < 0. 05). The levels of CD3, CD4 and CD8 in the observation group were significantly different from those in the control group after treatment (P0.05). There were significant differences in neutropenia nausea vomiting diarrhea and peripheral neurotoxicity between the two groups (P0.05). Conclusion: the combination of Fuzheng Jianpixiao Cancer recipe and mFOLFOX6 regimen in the treatment of advanced colorectal cancer patients has a significant effect in improving TCM symptoms, improving physical strength and quality of life, enhancing immune function, and can reduce the level of tumor markers in patients with colorectal cancer. At the same time, it can also alleviate some side effects of chemotherapy. The combination of traditional Chinese medicine (TCM) and chemotherapy is superior to chemotherapy alone in the treatment of advanced colorectal cancer, which provides an effective comprehensive treatment for advanced colorectal cancer.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.34

【相似文献】